NASDAQ:OMER - Omeros News Headlines

$15.47
+0.24 (+1.58 %)
(As of 07/17/2019 04:00 PM ET)
Today's Range
$15.12
Now: $15.47
$15.60
50-Day Range
$14.69
MA: $16.28
$18.49
52-Week Range
$10.30
Now: $15.47
$27.00
Volume12,807 shs
Average Volume407,628 shs
Market Capitalization$758.96 million
P/E RatioN/A
Dividend YieldN/A
Beta3.04

Headlines

Omeros (NASDAQ OMER) News Headlines

Source:
DateHeadline
Commit To Buy Omeros Corp At $14, Earn 31.5% Annualized Using Options - NasdaqCommit To Buy Omeros Corp At $14, Earn 31.5% Annualized Using Options - Nasdaq
www.nasdaq.com - July 15 at 7:30 PM
Omeros (NASDAQ:OMER) Rating Reiterated by WedbushOmeros (NASDAQ:OMER) Rating Reiterated by Wedbush
www.americanbankingnews.com - July 15 at 7:41 AM
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings - Yahoo FinanceThe Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings - Yahoo Finance
finance.yahoo.com - July 14 at 9:34 AM
Zacks: Analysts Anticipate Omeros Co. (NASDAQ:OMER) Will Announce Quarterly Sales of $28.29 MillionZacks: Analysts Anticipate Omeros Co. (NASDAQ:OMER) Will Announce Quarterly Sales of $28.29 Million
www.americanbankingnews.com - July 13 at 1:33 AM
Omeros Co. (NASDAQ:OMER) Expected to Post Earnings of -$0.38 Per ShareOmeros Co. (NASDAQ:OMER) Expected to Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - July 11 at 10:15 PM
Healthcare dominate premarket gainers - Seeking AlphaHealthcare dominate premarket gainers - Seeking Alpha
seekingalpha.com - July 11 at 5:52 PM
Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment - BenzingaOmeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment - Benzinga
www.benzinga.com - July 11 at 5:52 PM
Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage TreatmentOmeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment
finance.yahoo.com - July 11 at 5:52 PM
Calls Pop as Drug Stock Gets FDA BoostCalls Pop as Drug Stock Gets FDA Boost
finance.yahoo.com - July 11 at 5:52 PM
FDA on board with endpoint for pivot study of Omeros narsoplimab; shares up 12% premarket - Seeking AlphaFDA on board with endpoint for pivot study of Omeros' narsoplimab; shares up 12% premarket - Seeking Alpha
seekingalpha.com - July 11 at 9:11 AM
Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMAOmeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA
finance.yahoo.com - July 11 at 9:11 AM
Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of "Hold" from AnalystsOmeros Co. (NASDAQ:OMER) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 5 at 12:37 PM
Omeros: Full Steam Ahead - Seeking AlphaOmeros: Full Steam Ahead - Seeking Alpha
seekingalpha.com - June 27 at 9:26 AM
Traders Purchase Large Volume of Put Options on Omeros (NASDAQ:OMER)Traders Purchase Large Volume of Put Options on Omeros (NASDAQ:OMER)
www.americanbankingnews.com - June 26 at 6:27 AM
Form 4 OMEROS CORP For: Jun 07 Filed by: Demopulos Peter A MD - StreetInsider.comForm 4 OMEROS CORP For: Jun 07 Filed by: Demopulos Peter A MD - StreetInsider.com
www.streetinsider.com - June 12 at 12:31 PM
Form 4 OMEROS CORP For: Jun 07 Filed by: Cable Thomas J. - StreetInsider.comForm 4 OMEROS CORP For: Jun 07 Filed by: Cable Thomas J. - StreetInsider.com
www.streetinsider.com - June 12 at 12:31 PM
Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA - Yahoo FinanceOmeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA - Yahoo Finance
finance.yahoo.com - June 5 at 10:22 AM
Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMAOmeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
finance.yahoo.com - June 5 at 10:22 AM
Is Omeros Corporations (NASDAQ:OMER) CEO Paid At A Competitive Rate? - Yahoo FinanceIs Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate? - Yahoo Finance
finance.yahoo.com - May 29 at 5:39 PM
Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate?Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate?
finance.yahoo.com - May 29 at 5:39 PM
Obsessive-Compulsive Disorder Pipeline Review, H1 2019 Report Featuring Addex Therapeutics, Amorsa Therapeutics, Biohaven Pharmaceutical, & Omeros - ResearchAndMarkets.com - Yahoo FinanceObsessive-Compulsive Disorder Pipeline Review, H1 2019 Report Featuring Addex Therapeutics, Amorsa Therapeutics, Biohaven Pharmaceutical, & Omeros - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - May 23 at 10:20 AM
Omeros to Present at the UBS Global Healthcare Conference - Yahoo FinanceOmeros to Present at the UBS Global Healthcare Conference - Yahoo Finance
finance.yahoo.com - May 15 at 10:40 AM
Omeros to Present at the UBS Global Healthcare ConferenceOmeros to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 10:40 AM
Omeros (OMER) Q1 2019 Earnings Call Transcript - The Motley FoolOmeros (OMER) Q1 2019 Earnings Call Transcript - The Motley Fool
www.fool.com - May 12 at 9:34 AM
Omeros (OMER) Q1 2019 Earnings Call TranscriptOmeros (OMER) Q1 2019 Earnings Call Transcript
www.fool.com - May 11 at 3:49 PM
Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT - Yahoo FinanceEdited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT - Yahoo Finance
finance.yahoo.com - May 10 at 5:18 PM
Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMTEdited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT
finance.yahoo.com - May 10 at 5:17 PM
Omeros: 1Q Earnings Snapshot - Yahoo FinanceOmeros: 1Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - May 10 at 10:22 AM
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates - Yahoo FinanceOmeros (OMER) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 10 at 10:22 AM
Omeros Corporation Reports First Quarter 2019 Financial Results - Yahoo FinanceOmeros Corporation Reports First Quarter 2019 Financial Results - Yahoo Finance
finance.yahoo.com - May 10 at 10:22 AM
Omeros (OMER) CEO Greg Demopulos on Q1 2019 Results - Earnings Call Transcript - Seeking AlphaOmeros' (OMER) CEO Greg Demopulos on Q1 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 10 at 10:22 AM
Omeros (OMER) Reports Q1 Loss, Lags Revenue EstimatesOmeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 10 at 10:22 AM
Omeros down nearly 6% after missing estimatesOmeros down nearly 6% after missing estimates
seekingalpha.com - May 9 at 7:19 PM
Did Hedge Funds Drop The Ball On Omeros Corporation (OMER) ? - Yahoo FinanceDid Hedge Funds Drop The Ball On Omeros Corporation (OMER) ? - Yahoo Finance
finance.yahoo.com - May 9 at 5:27 PM
Omeros Corporation Reports First Quarter 2019 Financial Results - Business WireOmeros Corporation Reports First Quarter 2019 Financial Results - Business Wire
www.businesswire.com - May 9 at 5:27 PM
Omeros Q1 2019 Earnings Preview - Seeking AlphaOmeros Q1 2019 Earnings Preview - Seeking Alpha
seekingalpha.com - May 9 at 10:22 AM
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 - Yahoo FinanceOmeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 - Yahoo Finance
finance.yahoo.com - May 7 at 5:25 PM
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
finance.yahoo.com - May 7 at 10:14 AM
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual MeetingClinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
finance.yahoo.com - May 7 at 10:14 AM
Cantor Fitzgerald Starts Omeros Corp. (OMER) at Overweight - StreetInsider.comCantor Fitzgerald Starts Omeros Corp. (OMER) at Overweight - StreetInsider.com
www.streetinsider.com - May 6 at 9:27 AM
Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know - Yahoo FinanceWill Omeros (OMER) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
finance.yahoo.com - May 2 at 5:28 PM
Will Omeros (OMER) Report Negative Q1 Earnings? What You Should KnowWill Omeros (OMER) Report Negative Q1 Earnings? What You Should Know
finance.yahoo.com - May 2 at 5:28 PM
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting - Yahoo FinanceOmeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting - Yahoo Finance
finance.yahoo.com - May 1 at 10:06 AM
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual MeetingOmeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
finance.yahoo.com - May 1 at 10:06 AM
Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment - Business WireOmeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment - Business Wire
www.businesswire.com - April 3 at 4:54 PM
Omeros (OMER) Presents EBMT Case Report of Resolution of Gastrointestinal HSCT-TMA Following Narsoplimab Treatm - StreetInsider.comOmeros (OMER) Presents EBMT Case Report of Resolution of Gastrointestinal HSCT-TMA Following Narsoplimab Treatm - StreetInsider.com
www.streetinsider.com - April 3 at 4:54 PM
Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab TreatmentOmeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
finance.yahoo.com - April 3 at 12:45 PM
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation - Business WireOmeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation - Business Wire
www.businesswire.com - March 21 at 5:16 PM
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow TransplantationOmeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
finance.yahoo.com - March 19 at 11:12 AM
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
finance.yahoo.com - March 13 at 5:14 PM
This page was last updated on 7/17/2019 by MarketBeat.com Staff

Featured Article: Catch-Up Contributions

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel